We look forward to representing you in this case. During the course of this litigation, you authorize us to employ, share work and/or fees with other attorneys or law firms to prosecute your case. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. Should we obtain a favorable result, you authorize us to ask the court to award us compensation or seek reimbursement of expenses and up to one-third of any monetary class fund, or to negotiate and obtain a fee amount from defendants to be paid by the defendants, or its insurer or successor, but we will never ask you to pay any of the costs of this litigation.Īs the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees or costs. We agree to advance all expenses in the litigation, which means that you are not liable or responsible to pay any of the expenses of the action, whether attorneys’ fees or costs. throughout the litigation and/or closing of the transaction. hedge funds loaded up on SPACS, value stocks during first quarter May 17, 2021. prior to the recent takeover announcement and that you must maintain ownership in Montes Archimedes Acquisition Corp. As a named plaintiff, you acknowledge that you owned shares in Montes Archimedes Acquisition Corp. and/or its board of directors or officers. With a market capitalization of US500m, Montes Archimedes Acquisition is a small cap stock, so it might not be well known by many institutional investors.
Montes archimedes acquisition corp Pc#
This confirms that you have retained Monteverde & Associates PC to file an action with a complaint against Montes Archimedes Acquisition Corp. Biotech is a speculative business at the best of times, In this case, Roivant’s new investors will really be relying on faith.To start a Class Action lawsuit, please sign the Montes Archimedes Acquisition Corp. And if Ramaswamy manages to goose the market value of Roivant, he may be less worried about overpaying for Immunovant.
![montes archimedes acquisition corp montes archimedes acquisition corp](https://sec.report/Document/0001104659-21-085475/tm2119232d5_ex99-1img064.jpg)
But it also means that Roivant itself may get a valuation glow, if investors believe both that it has snagged a good deal and that Ramaswamy is, in general, good at identifying drugs that work.Ī big catch is that investors don’t actually know for sure whether Roivant’s information really is positive, or at least, positive enough to justify whatever premium it might offer. That means Roivant may have to pay up for Immunovant’s minority shares. Investors in both Roivant and Immunovant will naturally assume that the secret intel is positive. What is genuinely peculiar is that Roivant says it has nonpublic information about Immunovant. The presence of two SPACs is unusual, but mostly just reflects the fact that these companies are currently ubiquitous in capital markets. In this case, though, one of those investments is a listed company that Roivant thinks is undervalued.
Montes archimedes acquisition corp tv#
It uses the process to raise money on the promise of investing it profitably – in drugs, factories, TV shows or something else. The basic premise, seen from Roivant’s perspective, isn’t so different from any company going public.
![montes archimedes acquisition corp montes archimedes acquisition corp](https://sec.report/Document/0001104659-21-085475/tm2119232d5_ex99-1img068.jpg)
Roivant is raising money through its own go-public merger with another SPAC, Montes Archimedes Acquisition Corp. With a market capitalization of US507m, Montes Archimedes Acquisition is a small cap stock, so it might not be well known by many institutional investors. That could cost $1 billion, assuming a mark-up of a little more than 50%.
![montes archimedes acquisition corp montes archimedes acquisition corp](https://sec.report/Document/0001104659-21-085475/tm2119232d5_ex99-1img092.jpg)
Now Roivant, run by biotech entrepreneur Vivek Ramaswamy, plans to buy back the stake it doesn’t own at a premium appropriate for similar life-sciences deals.
![montes archimedes acquisition corp montes archimedes acquisition corp](https://sec.report/Document/0001104659-21-085475/tm2119232d5_ex99-1img106.jpg)
Roivant has about 58% of Immunovant, which at $1.5 billion is worth two-thirds less than it was at the end of last year, thanks mostly to a hitch in trials of its lead drug for autoimmune disease. At heart, what Roivant is doing is fairly simple – and risky for investors who join it for the ride. It plans to raise funds by merging with a listed special-purpose acquisition company and then may buy out minority investors in Immunovant, a drugmaker it floated two years ago via a sale to another blank-check vehicle. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition. Roivant Sciences has found a way to combine all three. SPACs, biotechnology and deals where insiders buy out minority investors are all at the more complex end of company finance.